LASER AI Selected by Cochrane

LASER AI Selected by Cochrane for AI Platform Study in Evidence Synthesis

Cochrane has selected LASER AI as one of two tools, chosen from 48 submissions, to participate in its AI platform study evaluating how artificial intelligence can support evidence synthesis.

The selection followed Cochrane's RAISE-aligned evaluation process, designed to assess AI tools against rigorous standards of methodological integrity, transparency, and responsible use. We are proud that LASER AI met that bar.

As Artur Nowak, Co-founder of Evidence Prime, put it in Cochrane's announcement: "The timing couldn't be better, and Cochrane is the right partner to lead such an evaluation. At a moment when AI agents are rapidly reshaping workflows, we're especially excited to benefit from Cochrane's decades of methodological leadership and contribute to achieving a better understanding of how these technologies can support evidence synthesis."

Cochrane author teams have already begun onboarding and training on LASER AI. Interim analyses are expected mid-2026, with results in the latter part of the year.

Evidence synthesis is a field that rightly holds its tools to a high standard. Being part of how that standard gets defined for AI - through independent, rigorous evaluation - is what we have been working toward.

We are grateful to the researchers, methodologists, and institutions who have trusted LASER AI in their work and helped us get here.

Read Cochrane's full announcement

‍